This discrepancy will not be shared with other dopamine reuptake inhbitors like bupropion, sibutramine, mazindol or tesofensine, which have related or bigger potencies than copyright as dopamine reuptake inhibitors. These conclusions have evoked a hypothesis that copyright can also purpose for a so-termed "DAT inverse agonist" or "unfavorable allos